Midland Animal Services is urging distemper vaccines to keep dogs safe
Canine distemper is a highly contagious and often fatal viral disease affecting dogs' respiratory, gastrointestinal, and nervous systems. Symptoms include nasal discharge, coughing, lethargy, and neurological signs.
Proper vaccination is the most effective defense against distemper. The American Animal Hospital Association (AAHA) recommends the following vaccination schedule for puppies and adult dogs:
Puppies (6-16 weeks): Administer at least three doses of the combination vaccine (Distemper, Adenovirus, Parvovirus) every 2-4 weeks, starting between 6 and 8 weeks of age.
Adult Dogs (older than 16 weeks): Two doses of the combination vaccine, 2-4 weeks apart, followed by a booster within one year, and subsequent boosters every three years.
To safeguard our community's pets, Midland Animal Services is implementing the following measures:
Vaccination Clinics: Encouraging pet owners to visit their local veterinarian to ensure pets are up-to-date on vaccinations. For low-cost options, Fix West Texas offers drive-thru vaccination services from 10 a.m. to noon on March 5-7, 14-19, and 24-30.
Public Education: MAS is distributing educational materials to raise awareness about the importance of vaccinations and to help pet owners recognize the early signs of distemper.
Shelter Protocols: To minimize the risk of outbreaks, MAS is enhancing biosecurity measures within its facilities.
Call to Action: Midland Animal Services strongly encourage all pet owners to:
Review Vaccination Records: Ensure your pets are current on all vaccinations, especially the distemper vaccine.
Limit Exposure: Avoid contact with unvaccinated or unknown-status dogs, particularly in communal settings.
Monitor Health: Be vigilant for symptoms such as nasal discharge, coughing, or lethargy, and consult a veterinarian promptly if concerns arise.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories. It also features its rapid next-generation sequencing (NGS) technology, recently approved by the U.S. Food and Drug Administration (FDA), the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer, for use as a companion diagnostic for Dizal's ZEGFROVY® (sunvozertinib) and for tumor profiling applications. 'Our solutions harness our scientific expertise to enhance care by enabling earlier and more precise detection and diagnosis. In partnership with our customers, we're working every day to bring better, faster and safer diagnostics to all patients,' said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. 'At Thermo Fisher, we are committed to advancing diagnostics that address today's most pressing global health challenges by boosting efficiency and reducing overall laboratory costs — ultimately driving more optimal patient care.' Harnessing Innovation for Quality Assurance, Efficiency and Sustainability in the Clinical Lab Clinical laboratories rely on quality assurance programs (QAPs) to ensure test result accuracy, which is essential for proper diagnosis and treatment. In resource-limited settings, a QAP that delivers quick, actionable insights can ease operational bottlenecks, improve workflow efficiency and enhance data-driven decisions. Thermo Fisher's new LabLink360 is a next-generation QAP software designed to help enhance patient safety, reduce errors and elevate healthcare quality. It features Sigma-metric analysis, a global benchmarking tool that helps labs assess performance and optimize quality control parameters based on results. Thermo Fisher also recently launched the Thermo Scientific MAS Omni•CORE ™ Max load-and-go quality controls (QC) to help simplify and automate lab workflows, allowing lab technicians to be more efficient and focus more on delivering fast and accurate patient results. The Omni•CORE Max QCs are part of a portfolio of QCs for clinical diagnostic testing, including the MAS Diabetes Max, which can help labs reduce daily QC bottles by up to 54% and lot-to-lot validations by up to 77%.** Beyond supporting the improved efficiency of laboratories, Thermo Fisher is also committed to supporting customers' sustainability initiatives. While most labs print patient results, QC, calibrations and other instrument data and place them in storage, this practice contributes to a staggering environmental impact. The company will present a poster and a micro-lecture explaining the transformative benefits of transitioning to a paperless laboratory environment. Targeting Unmet Diagnostic Needs Approximately 85% of patients in the U.S. receive cancer care in community settings. However, these sites have historically lacked consistent access to rapid and reliable next-generation sequencing, which is playing a growing role in informing precision oncology treatment decisions. At ADLM, the company will present its rapid NGS solution, the Oncomine Dx Express Test on the Ion Torrent Genexus Integrated Sequencer. Available as both an RUO solution and for clinical use on the Genexus Dx System, more care teams can now access NGS results in as little as 24 hours*** to help make more informed treatment recommendations for their patients, while also sparing patients from unnecessary delays, procedures and uncertainty. Also helping expand vital testing the company will highlight its PreClara™ Ratio,**** cleared in 2023 and previously known as B·R·A·H·M·S™ sFlt-1/PlGF KRYPTOR™ Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing. As the first FDA-cleared biomarker test for preeclampsia risk assessment, the PreClara Ratio provides reliable, quantifiable results with excellent analytical and clinical performance. When combined with other laboratory tests and standard clinical assessment, the PreClara Ratio may enable more informed clinical decisions, with the aim of improving health outcomes for both mothers and their babies. Thermo Fisher will also highlight its EXENT ® Solution, a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The EXENT Solution enables more sensitive analytical methods that can differentiate between patient subsets without requiring invasive bone marrow biopsy techniques too early. It is currently available for clinical use in Brazil, Belgium, France, Germany, Italy, the Netherlands, New Zealand, Spain, the United Kingdom, Switzerland and Australia. Thermo Fisher is also presenting its latest solutions for allergy and autoimmune diagnostics, oncology, women's health and quality control testing. In the booth, attendees can engage with a series of dynamic micro-lectures designed to advance industry knowledge and clinical expertise. These sessions cover a wide range of diagnostic topics and innovations, offering valuable insights into improving testing efficiency, patient outcomes and disease detection strategies. For more information on Thermo Fisher's activities at ADLM, please visit or conference booth (2812) to experience the full breadth of Thermo Fisher's diagnostic solutions. * Not yet commercially available. ** Will vary for each laboratory depending on the configuration. Data on file. ***Timing varies by number of samples and type of run. ****Brand trademarked in the U.S. only. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Yahoo
18-07-2025
- Yahoo
Novartis culls ianalumab in HS after Phase IIb trial failure
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint. The study (NCT03827798) had enrolled 248 patients with HS and was evaluating the change in simplified Hidradenitis Suppurativa Clinical Response (sHiSCR) after 16 weeks. The termination of the therapy in HS was announced in Novartis' Q2 results, with the company stating: 'Novartis will not advance investigation of ianalumab in HS following a Phase II proof-of-concept study which did not meet our target criteria despite demonstrating efficacy vs placebo. No new safety signals were observed, and all other studies for ianalumab in B-cell driven diseases continue as planned.' The indications Novartis will continue the development of ianalumab for include lupus nephritis, Sjögren syndrome, and autoimmune hepatitis. Ianalumab is a monoclonal antibody directed against the BAFF (B cell-activating factor belonging to the TNF family) receptor. It acts by preventing the activation of B cells to avoid overproduction. By reducing the number and activity of B cells, ianalumab can help to dampen the harmful immune responses that drive autoimmune diseases. If approved, GlobalData predicts ianalumab to reach sales of $638m in 2031. GlobalData is the parent company of Clinical Trials Arena. Four other pipeline drugs in Phase IIb study The Phase IIb trial also evaluated the efficacy of four other drugs in Novartis' pipeline, namely iscalimab, remibrutinib, LYS-006 and MAS-825. Data from the remibrutinib was presented at the American Academy of Dermatology (AAD) meeting in March 2024, with the drug having met its primary endpoint. As a result, Novartis is now running a Phase III trial of the therapy in HS (NCT06799000). Novartis has already secured a drug in the HS treatment space, after Cosentyx (secukinumab) gained approval from the US Food and Drug Administration (FDA) in October 2023. UCB's Bimzelx (bimekizumab) is the most recent biologic in HS, having been approved by the FDA in November 2024. AbbVie's flagship Humira (adalimumab) is also approved in HS and was the first biologic to be approved in the indication in 2015. "Novartis culls ianalumab in HS after Phase IIb trial failure" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
CBS News
14-07-2025
- CBS News
New Jersey woman opens up about experience with parvovirus, warns other moms-to-be
A little-known respiratory virus is spreading, mainly among children, and can be dangerous for pregnant women, according to the Centers for Disease Control and Prevention. Because parvovirus doesn't always have obvious symptoms, the CDC says pregnant women might want to consider wearing masks in crowded areas. Jackie Blalock was worried about her newborn baby Charlotte, who was delivered two weeks early because of a parvovirus infection. The special education teacher in South Jersey says the respiratory infection spread through her school and that seven students in her class had confirmed cases. She suspects she got the virus from sitting at a table with her students. The CDC says parvovirus B19 symptoms are mild or nonexistent. The most common sign of an infection is a facial rash. "The nickname is slapped cheek disease," Blalock said. "I looked like I was slapped across both cheeks." A blood test confirmed her case, and while it's usually not dangerous, parvovirus can be for pregnant women. "I was panicking for my unborn daughter," Blalock said, "There is a risk that the virus can pass across the placenta and infect the baby," Dr. Jenani Jayakumaran with Virtua Health said. Jayakumaran said parvovirus can cause serious complications and even death for an unborn baby. The CDC says there has been a continued increase in cases among teenagers and young adults and is warning pregnant people. "They recommend that patients consider masking as well as standard hygiene things like hand washing," Jayakumaran said. "I wish I had known ahead of time," Blalock said. "I would have worn a mask." Parvovirus is more commonly associated with an infection that affects dogs, but it can't spread between people and animals. "It's something no one talks about, so it is a little scary," Blalock said. "It is uncharted water." Doctors say Charlotte, who's a month old now, is fine, and Blalock is relieved. Blalock says she's now on a mission to warn pregnant women about the potential danger.
